The global metastatic ovarian cancer drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor accelerating the demand for these drugs include the growing prevalence of metastatic ovarian cancer. Ovarian cancer is the second most common gynecologic cancer in the US. The American Cancer Society (ACS) estimates that there will be nearly 19,880 women receiving a new diagnosis of ovarian cancer in the US. The current research in ovarian cancer is focused on using novel treatments such as immunotherapy, targeted therapy, and most importantly combination regimens. Immuno-oncologic agents have shown promising results with improved survival and lower toxicity. However, a single-agent response rate of PD-1/ PD-L1 molecules such as Opdivo and Keytruda for ovarian cancer treatment is less than 20.0%. 

Combination therapies, specifically those including checkpoint inhibitors, are poised to be introduced in the first-line setting to target major unmet needs including overcoming tumor resistance, improving progression-free survival, and maintaining the quality of life. The need for more effective treatment options is another factor that is fueling the growth of the market. While the market is dominated by generics such as paclitaxel and carboplatin, it is expected that drugs such as Bevacizumab (Avastin), Pazopanib (Votrient) would boost the growth of this market. The development of drugs with improved efficacy is a challenge for this market. The opportunity for this market lies in developing new drugs for treatment of metastatic ovarian cancer. 

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Product Type

o By Application 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  F. Hoffman La-Roche AG, Pfizer Inc., and Eisai Co., Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Metastatic Ovarian Cancer Drug Market Report by Segment

By Product Type

• E-7449
• Crizotinib 
• CMB-305
• G-305
• LV-305
• Others

By Application

• Hospital
• Clinic
• Others

Global Metastatic Ovarian Cancer Drug Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa